Multimeric dual-modality breast cancer diagnostic agents
View Patent ↗The present invention describes dual-modality probes. In particular, the present invention discloses hydroxyapatite specific multimeric bisphosphonate dual-modality MRI and optical probes.
1. A dual-modality probe having a formula selected from the group consisting of:
wherein
BP is a bisphosphonate;
L 1 , L 2 , L 3 , L 4 , and L 5 are linkers; wherein said bisphosphonate and said linkers are connected by amide bonds;
IRDye is a near infrared dye with wavelength in the range of 700-900 nm;
wherein said near infrared dye is selected from the group consisting of IRDye 78, IRDye 700DX, VivoTag-S 750, VivoTag-S 800, VivoTag-S 680, DY-750, DY-682, DY-675, Cypate, Cy7, Alexa Fluor 750, and Alexa Fluor 680; wherein said near infrared dye and said linkers are connected by amide bonds;
and
is a metal chelate independently selected from:
2. The dual-modality probe of claim 1 , wherein said linkers are selected from the group consisting of alkane, amino acid, —NHCO(CH 2 ) 5 —, polyethylene glycol, and polypropylene glycol.
3. The dual-modality probe of claim 1 , wherein said dual-modality probe is in a form of pharmaceutically acceptable salt, hydrate, or solvate.
4. The dual-modality probe of claim 1 , wherein M is selected from the group consisting of Cu, Fe, In, Mn, Tm, Yb, Y, Gd, and Eu.
5. The dual-modality probe of claim 1 , wherein M is a lanthanide.
6. The dual-modality probe of claim 1 , wherein said bisphosphonate is selected from the group consisting of alendronate, incadronate, neridronate, olpadronate, pamidronate, risedronate, and zoledronate.